F7

Coagulation factor VII · P08709 · F7 on Sugi Atlas →

123,774 patent compounds predicted against F7, 82,830 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL45701	0.56	18/20
SCHEMBL47171	0.46	16/20
SCHEMBL47229	0.47	13/20
SCHEMBL44985	0.39	11/20
SCHEMBL45587	0.41	10/20
SCHEMBL41549	0.44	8/20
SCHEMBL46885	0.40	8/20
Linolenic Acid (SCHEMBL15282)	1.00	7/20
Icosapent (SCHEMBL20469)	1.00	7/20
Docosapentaenoic Acid (SCHEMBL20748)	1.00	7/20
SCHEMBL25423	1.00	7/20
SCHEMBL37141	1.00	7/20
SCHEMBL37142	1.00	7/20
Linolenic Acid (SCHEMBL46586)	1.00	7/20
Docosapentaenoic Acid (SCHEMBL117315)	1.00	7/20
Icosapent (SCHEMBL120666)	1.00	7/20
Icosapent (SCHEMBL120667)	1.00	7/20
Linolenic Acid (SCHEMBL51037)	0.96	7/20
Linolenic Acid (SCHEMBL104457)	0.96	7/20
Linolenic Acid (SCHEMBL106610)	0.96	7/20

Clinical trials — most relevant to F7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal	PHASE4	COMPLETED
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis	PHASE4	COMPLETED
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）	PHASE4	RECRUITING
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography	PHASE4	UNKNOWN
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma	PHASE3	WITHDRAWN
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.	PHASE3	COMPLETED
Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor	PHASE3	UNKNOWN
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A	PHASE3	COMPLETED
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors	PHASE2	UNKNOWN
KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia	PHASE2	COMPLETED
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B	PHASE2	COMPLETED
Fiix-prothrombin Time for Monitoring Warfarin	PHASE2	COMPLETED
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia	PHASE2	COMPLETED
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State	PHASE1	COMPLETED
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment	PHASE1	COMPLETED
Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B	PHASE1	COMPLETED
A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection	PHASE1	COMPLETED
Treatment of Inherited Factor VII Deficiency	nan	COMPLETED
Correlation Between PT and INR to Factor 7	nan	UNKNOWN
Assays for and Reversal of New Anticoagulants	nan	COMPLETED
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital	nan	UNKNOWN
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)	nan	COMPLETED
Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation	nan	COMPLETED
Observational Registry of the Treatment of Glanzmann's Thrombasthenia	nan	COMPLETED
Diagnostic Accuracy Study of a Point-of-Care Test for Coagulation Function	nan	UNKNOWN
Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)	nan	COMPLETED
Pattern of Menorrhagic Female Attending the Hematology Unit in Assuit University Children Hospital	nan	NOT_YET_RECRUITING
Treatment of Congenital Factor VII Deficiency	nan	COMPLETED
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury	nan	COMPLETED
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a F7 binder may also engage these)

Protein	Name	Similarity
Q2F9P2	—	1.000	Q2F9P2 →
Q2F9P4	—	1.000	Q2F9P4 →
Q9GLP2	—	1.000	Q9GLP2 →
P00745	—	1.000	P00745 →
PROC	Vitamin K-dependent protein C	1.000	landscape →
P31394	—	1.000	P31394 →
P33587	—	1.000	P33587 →
P70375	—	1.000	P70375 →
Q8K3U6	—	0.999	Q8K3U6 →
Q28278	—	0.999	Q28278 →
P98139	—	0.999	P98139 →
P00743	—	0.999	P00743 →
P22891	—	0.998	P22891 →
Q28661	—	0.998	Q28661 →
Q80YC5	—	0.997	Q80YC5 →
Q3UZ09	—	0.995	Q3UZ09 →
P22457	—	0.994	P22457 →
F10	Coagulation factor X	0.993	landscape →
O97507	—	0.993	O97507 →
Q6IE64	—	0.993	Q6IE64 →
Q58L93	—	0.992	Q58L93 →
TMPRSS6	Transmembrane protease serine 6	0.992	landscape →
Q7RTY7	—	0.992	Q7RTY7 →
P04185	—	0.992	P04185 →
P49150	—	0.992	P49150 →
P11214	—	0.991	P11214 →
ST14	Suppressor of tumorigenicity 14 protein	0.991	landscape →
O88947	—	0.991	O88947 →
Q04962	—	0.991	Q04962 →
Q5R537	—	0.991	Q5R537 →